Key Highlights
- Krystal shares are trading down 13.32% at $288.04, against a previous close of $332.29.
- Vyjuvek Revenue rose 30% to $127.3 million, and EPS of $2.05 beat estimates.
- Board authorized a share repurchase program of up to $400 million over two years.
Krystal Biotech (NASDAQ:KRYS) shares are trading down 13.32% at $288.04, against a previous close of $332.29, even though the company reported third-quarter results above estimates. The shares swung from premarket gains to steep losses, with Volume around 2.5 times the average, and healthcare overall is little changed, so the drop looks specific to the stock.
Krystal Biotech, based in Pittsburgh, is a fully integrated, commercial-stage genetic medicines company. It uses a proprietary HSV-1 vector platform and in-house Manufacturing to develop redosable gene therapies for rare diseases with high unmet need. Its first product, Vyjuvek, is the first redosable gene therapy approved in the United States, Europe and Japan, for dystrophic epidermolysis bullosa. The company has about 295 employees.
Third-Quarter Results Beat Expectations
Global Vyjuvek net revenue was $127.3 million, up 30% from a year earlier and ahead of the $125.8 million estimate. U.S. revenue was $95.3 million and international revenue was $32 million. Diluted Earnings per Share of $2.05 compared with an estimate of $1.84, an 11.41% beat.
Gross Margin was 94%, against 96% a year earlier. Net Income was $63.1 million, down from $79.4 million, partly because the prior-year quarter benefited from non-recurring tax items. Cash and investments exceeded $1.2 billion, and the board authorized a repurchase program of up to $400 million, expected to be deployed over two years. Full-year non-GAAP Research and Development and SG&A guidance was lowered to $155 million to $165 million from $175 million to $195 million.
Commercial Rollout and Pipeline Timing
In the United States, Krystal added more than 80 new prescribers in the quarter, and about 80% of patients now self-administer. In Europe, pricing is concluded in Germany, where more than 20 centers have been initiated, and in Italy, where launch is expected in early 2027. A pricing decision in Spain is expected before year-end, and France is about six months into a typical 13-month negotiation. Japan is adding patients and prescribers, and a prescription-frequency restriction is expected to ease around November or December.
In the pipeline, the KB113 pilot in Gorlin syndrome showed regression in more than 80% of assessed lesions, including non-injected ones, and biopsies confirmed complete clearance of one injected tumor per patient. Management is engaging the FDA and expects a pivotal study of fewer than 100 patients. A data update for KB111 from five patients is expected by year-end, and the last patient visit in the ocular KB803 study is expected in February 2027, with top-line data and a BLA filing shortly after.
Delays Weigh on Sentiment
KB801 enrollment for neurotrophic keratitis is delayed by strict criteria and slow site activation, so enrollment completion and top-line results have moved to 2027. Interim data for the cystic fibrosis program KB407, including FEV1, is now expected in the first half of 2027, with a registrational study targeted to start in 2027. Interim data for the alpha-1 antitrypsin program KB408 are also expected in 2027, and the KB707 lung cancer expansion cohort expects to dose 70 patients by mid-2027. Management acknowledged that several readouts are taking longer than expected but said the studies are progressing well.
The stock trades near the middle of a 52-week range of $184.02 to $382.54, on a trailing price-to-earnings ratio of 39.06 and trailing earnings per share of $7.98. A beat on Vyjuvek revenue and earnings was not enough against high expectations and a pipeline calendar that has stretched.
The key questions now are whether Vyjuvek can sustain its growth as European and Japanese launches add revenue, how fast the buyback is deployed and whether the delayed pipeline readouts arrive on the new schedule.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...